| ²é¿´: 7967 | »Ø¸´: 3 | ||
jjz123456789Ìú³æ (³õÈëÎÄ̳)
|
[ÇóÖú]
ϸ°ûתȾÖеÄתȾÊÔ¼ÁPEIµÄ±£´æÎÊÌâ ÒÑÓÐ1È˲ÎÓë
|
| ÎÒÏÖÔÚÔÚ×öϸ°ûתȾ·½ÃæµÄʵÑ飬תȾÊÔ¼ÁÓõÄÊÇPEI£¬ÎÒÃǵÄPEIÅäÖóÉÈÜÒººó£¨Å¨¶È1mg/mL£©£¬·ÅÖÃÓÚ-20ÉãÊ϶ȱùÏäÖУ¬Ê¹ÓÃʱȡ³ö»á·¢ÏÖÓÐÎö³ö£¬ÓõϰµÃÔÙ´ÎÎÐÐý»ìÔÈ£¬ÄÇô£¬PEIÈÜÒº¿ÉÒÔÖ±½Ó±£´æÔÚ4ÉãÊ϶ȱùÏäÂð£¿Äܵϰ×î¶à¿ÉÒÔ±£´æ¶à³¤Ê±¼äÄØ£¿ |
» ²ÂÄãϲ»¶
Ò»Ö¾Ô¸ÎäÀí²ÄÁϹ¤³Ì348Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
08¹¤¿Æ 320×Ü·Ö Çóµ÷¼Á
ÒѾÓÐ11È˻ظ´
Ò»Ö¾Ô¸»ªÖÐũҵ071010£¬×Ü·Ö320Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
323Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
284Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
317Çóµ÷¼Á
ÒѾÓÐ16È˻ظ´
287Çóµ÷¼Á
ÒѾÓÐ9È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
308Çóµ÷¼Á
ÒѾÓÐ3È˻ظ´
»·¾³Ñ§Ë¶288Çóµ÷¼Á
ÒѾÓÐ6È˻ظ´
» ±¾Ö÷ÌâÏà¹ØÉ̼ÒÍÆ¼ö: (ÎÒÒ²ÒªÔÚÕâÀïÍÆ¹ã)
|
2Â¥2017-08-18 08:10:32
Ñô¹âzh
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 3 (Ó×¶ùÔ°)
- ½ð±Ò: 66.4
- ºì»¨: 1
- Ìû×Ó: 13
- ÔÚÏß: 8.6Сʱ
- ³æºÅ: 4329840
- ×¢²á: 2016-01-03
- רҵ: µ°°×ÖÊ×éѧ
3Â¥2017-08-30 08:24:19
biodrug
Òø³æ (СÓÐÃûÆø)
- Ó¦Öú: 1 (Ó×¶ùÔ°)
- ½ð±Ò: 413.4
- É¢½ð: 7
- ºì»¨: 2
- Ìû×Ó: 202
- ÔÚÏß: 61.9Сʱ
- ³æºÅ: 1296693
- ×¢²á: 2011-05-16
- רҵ: ºÏ³ÉÒ©Îﻯѧ
|
Polycystine-poly(His,Arg)1:5 (CHR) transfection of CHO-DG44 cells for the production of recombinant IgG antibody CHO-DG44 cells, CHO-K1 cells and MEFs CHR is composed of 100% amino acids,without any cytotoxic PEI. CHR-mediated transfection does not require complexpre-formation, works well in serum-containing media and is biodegradable, which may prevent cumulative cytotoxicity and facilitates downstream processing. |
4Â¥2023-04-05 11:26:38













»Ø¸´´ËÂ¥